EO9: A novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models

H.R. Hendriks, P.E. Pizao, D.P. Berger, K.L. Kooistra, M.C. Bibby, E. Boven, H.C. Dreef-Van der Meulen, R.E.C. Henrar, H.H. Fiebig, J.A. Double, H.W. Hornstra, H.M. Pinedo, P. Workman, G. Schwartsmann

Research output: Contribution to journalArticleAcademicpeer-review

4 Downloads (Pure)
Original languageEnglish
Pages (from-to)897-906
JournalEuropean Journal of Cancer
Volume29A
Issue number6
Publication statusPublished - 1993

Cite this

Hendriks, H. R., Pizao, P. E., Berger, D. P., Kooistra, K. L., Bibby, M. C., Boven, E., ... Schwartsmann, G. (1993). EO9: A novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models. European Journal of Cancer, 29A(6), 897-906.
Hendriks, H.R. ; Pizao, P.E. ; Berger, D.P. ; Kooistra, K.L. ; Bibby, M.C. ; Boven, E. ; Dreef-Van der Meulen, H.C. ; Henrar, R.E.C. ; Fiebig, H.H. ; Double, J.A. ; Hornstra, H.W. ; Pinedo, H.M. ; Workman, P. ; Schwartsmann, G. / EO9: A novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models. In: European Journal of Cancer. 1993 ; Vol. 29A, No. 6. pp. 897-906.
@article{22e4f6e0684748f383982d37cda4da47,
title = "EO9: A novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models",
author = "H.R. Hendriks and P.E. Pizao and D.P. Berger and K.L. Kooistra and M.C. Bibby and E. Boven and {Dreef-Van der Meulen}, H.C. and R.E.C. Henrar and H.H. Fiebig and J.A. Double and H.W. Hornstra and H.M. Pinedo and P. Workman and G. Schwartsmann",
year = "1993",
language = "English",
volume = "29A",
pages = "897--906",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Pergamon",
number = "6",

}

Hendriks, HR, Pizao, PE, Berger, DP, Kooistra, KL, Bibby, MC, Boven, E, Dreef-Van der Meulen, HC, Henrar, REC, Fiebig, HH, Double, JA, Hornstra, HW, Pinedo, HM, Workman, P & Schwartsmann, G 1993, 'EO9: A novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models' European Journal of Cancer, vol. 29A, no. 6, pp. 897-906.

EO9: A novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models. / Hendriks, H.R.; Pizao, P.E.; Berger, D.P.; Kooistra, K.L.; Bibby, M.C.; Boven, E.; Dreef-Van der Meulen, H.C.; Henrar, R.E.C.; Fiebig, H.H.; Double, J.A.; Hornstra, H.W.; Pinedo, H.M.; Workman, P.; Schwartsmann, G.

In: European Journal of Cancer, Vol. 29A, No. 6, 1993, p. 897-906.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - EO9: A novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models

AU - Hendriks, H.R.

AU - Pizao, P.E.

AU - Berger, D.P.

AU - Kooistra, K.L.

AU - Bibby, M.C.

AU - Boven, E.

AU - Dreef-Van der Meulen, H.C.

AU - Henrar, R.E.C.

AU - Fiebig, H.H.

AU - Double, J.A.

AU - Hornstra, H.W.

AU - Pinedo, H.M.

AU - Workman, P.

AU - Schwartsmann, G.

PY - 1993

Y1 - 1993

M3 - Article

VL - 29A

SP - 897

EP - 906

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 6

ER -